NCT04423302已完成不适用
Randomized Placebo-controlled Double-blinded Study of the Effect of TOTUM-63 on Glucose and Lipid Homeostasis in Subjects With Dysglycemia
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Valbiotis
- 入组人数
- 636
- 试验地点
- 88
- 主要终点
- Fasting plasma glucose concentration at V3 with a 3 times a day regimen
研究概览
简要总结
This clinical study aims to assess the efficacy of TOTUM-63, a mix of 5 plant extracts, consumed at the daily regimen of three times per day on glucose and lipid homeostasis in dysglycemic subjects. The hypothesis is that TOTUM-63, consumed 3 times per day, is superior to placebo for decrease of fasting plasma glucose (FPG) concentration after 24 weeks of consumption.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
盲法说明
2 blinded arms (Active 3 intakes per day and Placebo 3 intakes per day) and 1 open arm (Active 2 intakes per day)
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •From 18 to 70 years (including ranges);
- •Dysglycemic, prediabetic or newly diagnosed type 2 diabetes, subject without any clinical symptoms of diabetes (e.g. polyuria, polydipsia, blurred vision...) and not requiring immediate anti-diabetic treatment;
- •Body mass index (BMI) between 25 and 40 kg/m² (including ranges);
- •Waist circumference > 102 cm for men and > 88 cm for women (-2% margin allowed, respectively ≥ 100 cm and ≥ 86.5 cm);
- •Weight stable within ± 5% in the last three months;
- •No significant change in food habits or in physical activity in the 3 months before the randomization and agreeing to follow hygiene and dietary (HD) recommendations given during the study;
- •For women: Non-menopausal with the same reliable contraception since at least three months before the beginning of the study and agreeing to keep it during the entire duration of the study (hormonal contraception, intra uterine device or surgical intervention) or menopausal with or without hormone replacement therapy (estrogenic replacement therapy begun from less than 3 months excluded);
- •Good general and mental health according to the opinion of the investigator: no clinically significant and relevant abnormalities of medical history or physical examination;
- •Able and willing to participate to the study by complying with the protocol procedures as evidenced by his dated and signed informed consent form;
- •Affiliated with a social security scheme;
- •Agreeing to be registered on the volunteers in biomedical research (applicable only for French centers).
- •At V0 biological analysis, the subjects will be eligible to the study on the following criteria:
- •Fasting plasma glucose concentration ≥ 110 mg/dL.
排除标准
- •Suffering from a metabolic disorder such as treated diabetes, uncontrolled thyroidal dysfunction or other metabolic disorder needing a dose adjustment in drug intervention according to the professional recommendations;
- •Suffering from an uncontrolled arterial hypertension (systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg);
- •With a history of retinopathy, ischemic cardiovascular event, having undergone recent surgical procedure in the past 6 months or in the 9 months to come;
- •Suffering from a severe chronic disease (e.g. cancer, HIV, renal failure, hepatic or biliary disorders ongoing, chronic inflammatory digestive disease, arthritis or other chronic respiratory trouble, etc.) or gastrointestinal disorders found to be inconsistent with the conduct of the study by the investigator (e.g. celiac disease);
- •Under antidiabetic drug (e.g. biguanides, sulfonylureas, glinides, gliptins, glitazones, gliflozins, α-glucosidase inhibitors, incretins and insulin);
- •Under lipid-lowering treatment (e.g. statins, fibrates, ezetimibe, bile acid sequestrants, niacin, etc.) since less than 3 months or modification of the treatment dose since less than 3 months before the randomization. Subject with a stable lipid-lowering treatment since at least three months can be included in the study;
- •Under medication which could affect glucose and/or lipid homeostasis parameters or stopped less than 3 months before randomization (e.g. beta 2 agonists like salbutamol, Angiotensin Converting Enzyme (ACE) inhibitors, beta blockers, thiazide diuretics, Selective Serotonin Reuptake Inhibitors (SSRIs), Mono-Amine Oxidase Inhibitors (MAOIs), neuroleptics, long-term corticosteroid systemic drugs, systemic antibodies, androgens, phenytoin, interferons, immunosuppressants, antivirals and antiretrovirals, etc.):
- •Beta 2 agonists like salbutamol, ACE inhibitors, beta blockers, thiazide diuretics, SSRIs, MAOIs are tolerated only if stable since more than 3 months before the randomization and maintained during the whole study;
- •The others drugs (neuroleptics, long-term corticosteroid systemic drugs, systemic antibodies, androgens, phenytoin, interferons, immunosuppressants, antivirals and antiretrovirals, etc.) are not allowed during the study;
- •Regular intake of dietary supplements or "health foods", or products rich in plant stanol or sterol (like Pro-Activ® or Danacol® products), rich in long chain omega-3 fatty acids (especially soft gels containing fish oils), or in other substances intended to reduce glycemia (e.g. beta-glucans, konjac, olive leaf extract, berberine, cinnamon, etc.) or stopped less than 3 months before the randomization;
- •Under treatment or dietary supplement which could significantly affect parameter(s) followed during the study according to the investigator or stopped in a too short period before the randomization (for example consumed in the month before the randomization);
- •With a known or suspected food allergy or intolerance or hypersensitivity to any of the study products' ingredient;
- •Consuming more than 3 standard drinks daily of alcoholic beverage for men or 2 standard drinks daily for women or not agreeing to keep his alcohol consumption habits unchanged throughout the study;
- •With extreme and/or unbalanced eating habits (e.g. vegetarian, vegan, skipping meals regularly);
- •With a personal history of anorexia nervosa, bulimia or significant eating disorders according to the investigator;
- •Smoking more than 20 cigarettes daily or not agreeing to keep his smoking habits unchanged throughout the study. The subject should be able not to smoke during the visits (maximum 4 hours);
- •Having a lifestyle deemed incompatible with the study according to the investigator including high level of physical activity (defined as more than 10 hours of intense physical activity a week, walking excluded);
- •Pregnant (as evidenced by a positive test for β-HCG (Human Chorionic Gonadotropin), i.e. > 5 mUI/mL, realized at V0) or lactating women or intending to become pregnant within 9 months ahead;
- •Who made a blood donation in the 3 months before the randomization or intending to make it within 9 months ahead;
- •Taking part in another clinical trial or being in the exclusion period of a previous clinical trial;
- •Having received, during the last 12 months, indemnities for clinical trial higher or equal to 4500 Euros (applicable only for French centers);
- •Under legal protection (guardianship, wardship) or deprived from his rights following administrative or judicial decision;
- •Presenting a psychological or linguistic incapability to sign the informed consent;
- •Impossible to contact in case of emergency;
- •Any condition assessed by the investigator which could endanger patient safety or the conduct of the study (e.g. device related contraindication for impedancemetry and/or DEXA (Dual-Energy X-ray Absorptiometry) such as pacemaker or electronic implant);
- •At V0 biological analysis, the subjects will be considered as non-eligible to the study on the following criteria:
- •Fasting glucose plasma concentration > 220 mg/dL;
- •Fasting blood triglycerides > 2.2 g/L;
- •TSH (Thyroid Stimulating Hormone) outside the laboratory normal values;
- •Fasting blood LDL (Low Density Lipoprotein) cholesterol > 1.9 g/L or non HDLc (High Density Lipoprotein cholesterol) > 2.2 g/L or any condition requiring a therapeutic dose adjustment during the trial according to the professional recommendations;
- •Blood AST (ASpartate amino Transferase), ALT (ALanine amino Transferase) or GGT (Gamma Glutamyl Transpeptidase) > 3 x ULN (Upper Limit of Normal);
- •Blood creatinine concentration > 125 μmol/L;
- •eGFR estimated Glomerular Filtration Rate, calculated by CKD-EPI (Chronic Kidney Disease-EPIdemiology collaboration) formula) < 60 mL/min/1.73m²;
- •Complete blood count (CBC) with hemoglobin < 11 g/dL or leucocytes < 3000 /mm3 or leucocytes > 16000 /mm3 or clinically significant abnormality according to the investigator.
结局指标
主要结局
Fasting plasma glucose concentration at V3 with a 3 times a day regimen
时间窗: V3 (24 weeks of intervention)
Fasting plasma glucose concentration in mg/dL, TOTUM-63 3/day vs placebo
次要结局
- Evolution of the fasting insulinemia(V1 (baseline), V2 (12 weeks of intervention) and V3 (24 weeks of intervention))
- Evolution of the fasting blood concentrations of triglycerides(V1 (baseline), V2 (12 weeks of intervention) and V3 (24 weeks of intervention))
- Evolution of the HbA1c(V1 (baseline), V2 (12 weeks of intervention) and V3 (24 weeks of intervention))
- Evolution of the fasting plasma glucose concentration(V1 (baseline), V2 (12 weeks of intervention) and V3 (24 weeks of intervention))
- Evolution of the glycemia at 120 minutes following the 75g glucose intake(V1 (baseline), V2 (12 weeks of intervention), V3 (24 weeks of intervention) and V4 (12 weeks and the end of intervention))
- Evolution of the HOMA-IR (HOmeostasis Model Assessment of Insulin Resistance) index(V1 (baseline), V2 (12 weeks of intervention) and V3 (24 weeks of intervention))
- Evolution of the HOMA-β (Homeostasis Model Assessment of Beta cells) index(V1 (baseline), V2 (12 weeks of intervention) and V3 (24 weeks of intervention))
- Evolution of the QUICKY (QUantitative Insulin sensitivity ChecK Index) index(V1 (baseline), V2 (12 weeks of intervention) and V3 (24 weeks of intervention))
- Evolution of the fasting blood concentrations of free fatty acids(V1 (baseline), V2 (12 weeks of intervention) and V3 (24 weeks of intervention))
- Evolution of the fasting blood concentrations of total cholesterol(V1 (baseline), V2 (12 weeks of intervention) and V3 (24 weeks of intervention))
- Evolution of the fasting blood concentrations of HDL cholesterol(V1 (baseline), V2 (12 weeks of intervention) and V3 (24 weeks of intervention))
- Evolution of the fasting blood concentrations of non-HDL cholesterol(V1 (baseline), V2 (12 weeks of intervention) and V3 (24 weeks of intervention))
- Evolution of the fasting blood concentrations of LDL cholesterol(V1 (baseline), V2 (12 weeks of intervention) and V3 (24 weeks of intervention))
- Evolution of atherogenic index(V1 (baseline), V2 (12 weeks of intervention) and V3 (24 weeks of intervention))
- Evolution of cardiac risk ratio 2(V1 (baseline), V2 (12 weeks of intervention) and V3 (24 weeks of intervention))
- Evolution of the body composition assessed by impedancemeter(V1 (baseline), V2 (12 weeks of intervention) and V3 (24 weeks of intervention))
- Evolution of the body weight(V1 (baseline), V2 (12 weeks of intervention) and V3 (24 weeks of intervention))
- Evolution of the hip circumference(V1 (baseline), V2 (12 weeks of intervention) and V3 (24 weeks of intervention))
- Evolution of the waist to hip ratio(V1 (baseline), V2 (12 weeks of intervention) and V3 (24 weeks of intervention))
- Proportion of subjects having an improvement or a deterioration of their glycemic status from V1(V1 (baseline), V2 (12 weeks of intervention) and V3 (24 weeks of intervention))
- Evolution of atherogenic coefficient(V1 (baseline), V2 (12 weeks of intervention) and V3 (24 weeks of intervention))
- Evolution of the fasting blood concentrations of hsCRP(V1 (baseline), V2 (12 weeks of intervention) and V3 (24 weeks of intervention))
- Delay of occurence of pharmacological treatment requirement for type 2 diabetes from V1(V1 (baseline), V2 (12 weeks of intervention) and V3 (24 weeks of intervention))
- Evolution of Cardiac risk ratio 1(V1 (baseline), V2 (12 weeks of intervention) and V3 (24 weeks of intervention))
- Evolution of the waist circumference(V1 (baseline), V2 (12 weeks of intervention) and V3 (24 weeks of intervention))
研究者
研究点 (88)
Loading locations...
相似试验
Unknown
不适用
Effect of TOTUM-854 on Blood Pressure in Subjects With Moderately Elevated Blood PressurePrehypertensionElevated Blood PressureBlood PressureMetabolic SyndromeNCT05469503Valbiotis410
已完成
不适用
Mode of Action (MoA) Study of TOTUM-63 in Individuals at Increased Cardio-metabolic RiskPrediabetic StateDysglycemiaOverweight and ObesityNCT05369585Valbiotis20
招募中
不适用
Effects of TOTUM-448 on Liver Fat Content, Cardiometabolic Risk Factors and Gut Microbiota Among Participants with MASLDNon-Alcoholic Fatty Liver DiseaseNCT06704321Valbiotis70
已完成
不适用
Effect of Totum-070 on Lipid Metabolism in Moderate Hypercholesterolemic SubjectsHypercholesterolemiaCardiovascular Risk FactorDyslipidemiasOverweight and ObesityAtherosclerosisNCT04760951Valbiotis120
Unknown
不适用
Effect of the Food Supplement TOTUM-070 on Lipid MetabolismHypercholesterolemiaNCT06243484Valbiotis180